PuSH - Publikationsserver des Helmholtz Zentrums München

Zacchetti, A.* ; Coliva, A.* ; Luison, E.* ; Seregni, E.* ; Bombardieri, E. ; Giussani, A. ; Figini, M.* ; Canevari, S.*

177Lu-labeled MOv18 as compared to 131I- or 90Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts.

Nucl. Med. Biol. 36, 759-770 (2009)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
The mouse monoclonal antibody MOv18, directed against the alpha-isoform of folate receptor (FR), was investigated to identify the optimal radioconjugate for radioimmunotherapy of minimal residual disease in ovarian cancer. Methods: Pharmacokinetics, biodistribution, long-term therapeutic efficacy and toxicity of MOv18, labeled with the beta-emitters I-131, Y-90 and Lu-177, were compared in a xenografted mouse model, composed by two cell lines, A431FR and A431MK, differing only for FR expression. Results: A shorter blood clearance and a higher tumor uptake were observed for Y-90- and Lu-177- compared to I-131-MOv18, and a shorter blood pharmacokinetics was recorded in A431FR-bearing animals. At equitoxic maximum tolerable doses, the general irradiation by I-131- and Y-90-MOv18 gives rise to strong targeted effects on A431FR and nontargeted effects on A431MK tumors, while Lu-177-MOv18 was able to eradicate small size tumor masses expressing the antigen of interest exerting only mild non-targeted effects. Conclusion: Lu-177-MOv18 at the maximal tolerated dose is the immunoradioconjugate with the best therapeutic window in experimental conditions of small tumor volume.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Ovarian cancer; Monoclonal antibody MOv18; Radioimmunotherapy; Radiometals; Folate Receptor; monoclonal-antibody MOV18; ovarian-cancer; nude-mice; colorectal-cancer; radioimmunotherapy; carcinoma; efficacy; binding; model; Y-90
ISSN (print) / ISBN 0969-8051
e-ISSN 0969-8051
Zeitschrift Nuclear Medicine and Biology
Quellenangaben Band: 36, Heft: 7, Seiten: 759-770 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort New York
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Radiation Protection (ISS)